BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27414060)

  • 21. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
    Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
    Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic significance of the NPM-ALK fusion gene in bone marrow and peripheral blood for patients with anaplastic large cell lymphoma].
    Yang J; Zhao XX; Jin L; Duan YL; Huang S; Zhang M; Zhang R; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):700-3. PubMed ID: 23978023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.
    Pittaluga S; Wlodarska I; Pulford K; Campo E; Morris SW; Van den Berghe H; De Wolf-Peeters C
    Am J Pathol; 1997 Aug; 151(2):343-51. PubMed ID: 9250148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
    Damm-Welk C; Schieferstein J; Schwalm S; Reiter A; Woessmann W
    Br J Haematol; 2007 Aug; 138(4):459-66. PubMed ID: 17608768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
    Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
    Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
    Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
    Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
    Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
    Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
    Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of carbohydrate antigens, p80NPM/ALK, cytotoxic cell-associated antigens, and Epstein-Barr virus gene products in anaplastic large cell lymphomas.
    Kasai K; Kon S; Kikuchi K; Sato Y; Kameya T
    Pathol Int; 1998 Mar; 48(3):171-8. PubMed ID: 9589484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
    Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
    J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
    Chiarle R; Martinengo C; Mastini C; Ambrogio C; D'Escamard V; Forni G; Inghirami G
    Nat Med; 2008 Jun; 14(6):676-80. PubMed ID: 18469826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
    Babin L; Darchen A; Robert E; Aid Z; Borry R; Soudais C; Piganeau M; De Cian A; Giovannangeli C; Bawa O; Rigaud C; Scoazec JY; Couronné L; Veleanu L; Cieslak A; Asnafi V; Sibon D; Lamant L; Meggetto F; Mercher T; Brunet E
    Mol Cancer; 2022 Mar; 21(1):65. PubMed ID: 35246138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
    Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
    Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma.
    Ait-Tahar K; Barnardo MC; Pulford K
    Cancer Res; 2007 Mar; 67(5):1898-901. PubMed ID: 17332315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
    Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
    Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
    Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
    Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
    Falini B; Bigerna B; Fizzotti M; Pulford K; Pileri SA; Delsol G; Carbone A; Paulli M; Magrini U; Menestrina F; Giardini R; Pilotti S; Mezzelani A; Ugolini B; Billi M; Pucciarini A; Pacini R; Pelicci PG; Flenghi L
    Am J Pathol; 1998 Sep; 153(3):875-86. PubMed ID: 9736036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.